The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective analysis of institutional outcomes with FOLFIRINOX versus nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer.
 
Amisha Singh
No Relationships to Disclose
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Seagen; Seagen; Seagen; Seagen
Research Funding - Agios; Agios; Agios; Agios; Exelixis; Exelixis; Exelixis; Exelixis; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Ali McBride
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene